If approved, zavegepant nasal spray would be the only FDA-approved CGRP receptor antagonist in an intranasal formulation, giving patients a new treatment option that provides ultra-rapid pain relief in as little as 15 minutes that lasts…Original Article
US FDA Accepts for Review Biohaven’s New Drug Application (NDA) Filing of Intranasal Zavegepant for the Treatment of Migraine
